Nautilus Neurosciences may be a new name in the pharmaceutical business, but our people are seasoned industry veterans. Our company is built on a firm foundation of experience and expertise.
Nautilus is not “big pharma,” and that’s by design. Being small allows us to be exceptionally responsive and intimately engaged with our customers. Yet it doesn’t prevent us from delivering results—for patients, for neurologists and other physicians, for nurses, for investors, and for all our constituents. Ultimately, this is our goal: developing products—and the value of products—in the field of neurology for the benefit of all.
Nautilus is backed by Tailwind Capital and Galen Partners, leading private-equity firms. In the first half of 2010, we launched a novel product, CAMBIA™ (diclofenac potassium for oral solution) for the relief of migraine symptoms.